Clinical Outcome After Crush Versus Culotte Stenting of Coronary Artery Bifurcation Lesions

Abstract

At 36-month follow-up, the clinical outcomes were similar for patients with coronary bifurcation lesions treated with the culotte or the crush stent technique. (Nordic Bifurcation Study. How to Use Drug Eluting Stents [DES] in Bifurcation Lesions? NCT00376571).

Definite stent thrombosis after drug‐eluting stent implantation in coronary bifurcation lesions: A meta‐analysis of 3,107 patients from 14 randomized trials

“…Multiple studies have been designed to compare different DS strategies. The Nordic II study showed that definite ST was lower in the crush (1.4%) versus the culotte group (4.7%) respectively; however, this did not reach statistical significance ( P = 0.09) . The DKCRUSH‐III study reported a significantly increased definite ST rate (3.4%) in the culotte group versus DK crush group (0%; P = 0.007) .…”

COmplex coronary Bifurcation lesions: RAndomized comparison of a strategy using a dedicated self-expanding biolimus-eluting stent versus a culotte strategy using everolimus-eluting stents: primary results of the COBRA trial

“…Indeed, large-scale direct comparisons of BP-BES with the thinner-strut PP-EES have shown similar safety and efficacy at one year 10,18 , and the further increment of definite stent thrombosis from one to five years in the LEADERS trial was limited to 0.7%, suggesting a very low risk of stent thrombosis after the first year 9 . Similarly, the definite stent thrombosis rate three years after treatment of coronary bifurcation lesions with Axxess in combination with first-generation sirolimus-eluting 20 .…”

Intravascular ultrasound-guided percutaneous coronary intervention in left main coronary bifurcation lesions: a review

“…The randomized Nordic-Baltic IV 65 trial showed a trend toward improved midterm outcome when using a two-stent technique compared to provisional stenting in bifurcations with large SBs (≥2.75 mm) having >50% diameter stenosis in the SB. A similar signal was supported by the DKCRUSH II trial 16 and by a subgroup analysis of the Tryton IDE study 63 (EuroPCR 2014).…”